Time to reconsider the role of ribavirin in Lassa fever.
PLoS Neglected Tropical Diseases, 2021 Ribavirin is the only available Lassa fever treatment. The rationale for using ribavirin is based on one clinical study conducted in the early 1980s. However, reanalysis of previous unpublished data reveals that ribavirin may actually be harmful in some ...
Alex Paddy Salam +5 more
doaj +2 more sources
Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis [PDF]
DiseasesBackground: There is still debate whether ribavirin should be added to direct-acting antivirals (DAAs) for the management of treatment-experienced individuals with non-genotype-1 hepatitis C.
Shahd Hamran +10 more
doaj +2 more sources
Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysis
International Journal of Infectious Diseases, 2019 Objectives: Lassa fever (LF) causes annual outbreaks in endemic regions with high mortality of symptomatic patients. Ribavirin is recommended as standard treatment for LF in national and international guidelines but the evidence base for this ...
Kirsten Alexandra Eberhardt +2 more
exaly +3 more sources
Frontiers in Public Health, 2021 Background: Intravenous (IV) ribavirin is not approved in US and European Union, but it is authorized in China. Significant teratogenic and embryocidal effects of ribavirin have been found in almost all animal studies, it is critical to investigate the ...
Hailong Li +5 more
doaj +1 more source
Ribavirin enhances the action of interferon-α against hepatitis C virus by promoting the p53 activity through the ERK1/2 pathway. [PDF]
PLoS ONE, 2012 Background/aimsRibavirin significantly enhances the antiviral response of interferon-α (IFN-α) against Hepatitis C virus (HCV), but the underlying mechanisms remain poorly understood. Recently, p53 has been identified as an important factor involving the
Wei-Liang Liu +8 more
doaj +1 more source
Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy. [PDF]
PLoS Computational Biology, 2011 The current standard of care for hepatitis C virus (HCV) infection - combination therapy with pegylated interferon and ribavirin - elicits sustained responses in only ∼50% of the patients treated.
Sheeja M Krishnan, Narendra M Dixit
doaj +1 more source
A randomized, placebo‐controlled study to evaluate safety and pharmacokinetics of inhaled ribavirin
Clinical and Translational Science, 2022 Ribavirin is an inosine monophosphate dehydrogenase inhibitor. Studies suggest ribavirin aerosol could be a safe and efficacious treatment option in the fight against coronaviruses. However, current treatment is long (12–18 h per day, 3–7 days), limiting
Peter Couroux +6 more
doaj +1 more source
Inhibition of tick-borne encephalitis virus in cell cultures by ribavirin
Frontiers in Microbiology, 2023 Tick-borne encephalitis virus (TBEV) belonging to arboviruses is a major member of zoonotic pathogens. TBEV infection causes severe human encephalitis without specific antiviral drugs.
Wan-Da Tang +5 more
doaj +1 more source
Drug Target Insights, 2007 The effect of the antiviral agent ribavirin given alone or in combination with Silymarin on the development of liver injury induced in rats with carbon tetrachloride (CCl 4 ; 2.8 ml/kg followed by 1.4 ml/kg after one week) was studied. Ribavirin at three
Omar M.E. Abdel Salam M.D., Ph.D. +3 more
doaj +2 more sources
Selection of hepatitis C virus resistant to ribavirin
Virology Journal, 2011 Background Given the side effects associated with intravenous injections of interferon, an interferon-free regimen for the treatment of HCV infections is highly desirable.
Feinstone Stephen M +2 more
doaj +1 more source